In the context of potential application of NGF in glaucoma, the safety of an 8-week treatment with 180 μg/ml recombinant human NGF (rhNGF) eye drop solution was tested in a masked, randomized, vehicle-controlled, phase Ib trial of 60 participants with chronic POAG (NCT02855450); for now, the conclusions of this study have not yet been published (Table 2 and Figure 3). Here, NGF is linked to glaucoma.